Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis.

Ioannou GN, Landis CS, Jin GY, Haigh WG, Farrell GC, Kuver R, Lee SP, Savard C.

Hepatol Commun. 2019 Apr 1;3(6):776-791. doi: 10.1002/hep4.1348. eCollection 2019 Jun.

2.

Non-alcoholic fatty liver disease.

Farrell GC, Wardell R, Teoh N, Chitturi S.

Intern Med J. 2019 May;49(5):681-683. doi: 10.1111/imj.14283. No abstract available.

PMID:
31083812
3.

Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis.

de Haan L, van der Lely SJ, Warps AK, Hofsink Q, Olthof PB, de Keijzer MJ, Lionarons DA, Mendes-Dias L, Bruinsma BG, Uygun K, Jaeschke H, Farrell GC, Teoh N, van Golen RF, Li T, Heger M.

J Clin Transl Res. 2018 May 28;4(1):1-46. doi: 10.18053/jctres.04.201801.001. Epub 2018 Feb 16.

4.

The damage-associated molecular pattern HMGB1 is released early after clinical hepatic ischemia/reperfusion.

van Golen RF, Reiniers MJ, Marsman G, Alles LK, van Rooyen DM, Petri B, Van der Mark VA, van Beek AA, Meijer B, Maas MA, Zeerleder S, Verheij J, Farrell GC, Luken BM, Teoh NC, van Gulik TM, Murphy MP, Heger M.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1192-1200. doi: 10.1016/j.bbadis.2019.01.014. Epub 2019 Jan 15.

PMID:
30658161
5.

Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis.

Poekes L, Gillard J, Farrell GC, Horsmans Y, Leclercq IA.

Lab Invest. 2019 Jan;99(1):4-16. doi: 10.1038/s41374-018-0120-x. Epub 2018 Sep 26.

6.

Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.

Farrell GC, Haczeyni F, Chitturi S.

Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3. Review.

PMID:
29956204
7.

Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature.

Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, Yu J, Teoh NC, Farrell GC.

J Gastroenterol Hepatol. 2018 Jul;33(7):1312-1320. doi: 10.1111/jgh.14122. Epub 2018 Mar 24. Review.

8.

The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.

Haczeyni F, Wang H, Barn V, Mridha AR, Yeh MM, Haigh WG, Ioannou GN, Choi YJ, McWherter CA, Teoh NC, Farrell GC.

Hepatol Commun. 2017 Jul 31;1(7):663-674. doi: 10.1002/hep4.1072. eCollection 2017 Sep.

9.

Causes and mechanisms of adipocyte enlargement and adipose expansion.

Haczeyni F, Bell-Anderson KS, Farrell GC.

Obes Rev. 2018 Mar;19(3):406-420. doi: 10.1111/obr.12646. Epub 2017 Dec 15. Review.

PMID:
29243339
10.

TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.

Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC, Farrell GC.

Clin Sci (Lond). 2017 Jul 24;131(16):2145-2159. doi: 10.1042/CS20160838. Print 2017 Aug 15.

PMID:
28687713
11.

Deriving and testing of dysplastic murine hepatocytes: A new platform in liver cancer research.

Pok S, Vohra H, Wehbe C, Barn VA, Arfianti E, Dan YY, Farrell GC, Teoh NC.

Exp Cell Res. 2017 Jul 1;356(1):48-56. doi: 10.1016/j.yexcr.2017.04.009. Epub 2017 Apr 10.

PMID:
28408319
12.

Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.

Ioannou GN, Subramanian S, Chait A, Haigh WG, Yeh MM, Farrell GC, Lee SP, Savard C.

J Lipid Res. 2017 Jun;58(6):1067-1079. doi: 10.1194/jlr.M072454. Epub 2017 Apr 12.

13.

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.

Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):56-67. doi: 10.1016/S2468-1253(16)30011-5. Epub 2016 Aug 10. Review.

PMID:
28404113
14.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC.

J Hepatol. 2017 May;66(5):1037-1046. doi: 10.1016/j.jhep.2017.01.022. Epub 2017 Feb 3.

15.

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.

Haczeyni F, Poekes L, Wang H, Mridha AR, Barn V, Geoffrey Haigh W, Ioannou GN, Yeh MM, Leclercq IA, Teoh NC, Farrell GC.

Obesity (Silver Spring). 2017 Jan;25(1):155-165. doi: 10.1002/oby.21701. Epub 2016 Nov 2.

16.

Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese mice.

Poekes L, Legry V, Schakman O, Detrembleur C, Bol A, Horsmans Y, Farrell GC, Leclercq IA.

Clin Sci (Lond). 2017 Feb 1;131(4):285-296. doi: 10.1042/CS20160469. Epub 2016 Nov 1.

PMID:
27803297
17.

Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.

Truong J, Shadbolt B, Ooi M, Chitturi S, Kaye G, Farrell GC, Teoh NC.

Intern Med J. 2017 Jan;47(1):50-56. doi: 10.1111/imj.13244.

PMID:
27571991
18.

Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κB or Akt/mTORC1.

Arfianti E, Larter CZ, Lee S, Barn V, Haigh G, Yeh MM, Ioannou GN, Teoh NC, Farrell GC.

J Clin Transl Res. 2016 Jan 19;2(1):26-37. eCollection 2016 Apr 15.

19.

Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis.

Pok S, Barn VA, Wong HJ, Blackburn AC, Board P, Farrell GC, Teoh NC.

J Gastroenterol Hepatol. 2016 Jun;31(6):1210-9. doi: 10.1111/jgh.13232.

PMID:
26574916
20.

Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice.

Haczeyni F, Barn V, Mridha AR, Yeh MM, Estevez E, Febbraio MA, Nolan CJ, Bell-Anderson KS, Teoh NC, Farrell GC.

Obesity (Silver Spring). 2015 Sep;23(9):1845-55. doi: 10.1002/oby.21170. Epub 2015 Aug 6.

21.

Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating eNOS and microparticle formation.

Ajamieh H, Farrell GC, McCuskey RS, Yu J, Chu E, Wong HJ, Lam W, Teoh NC.

Liver Int. 2015 Sep;35(9):2174-86. doi: 10.1111/liv.12827. Epub 2015 Apr 7.

PMID:
25786512
22.

Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.

Ioannou GN, Van Rooyen DM, Savard C, Haigh WG, Yeh MM, Teoh NC, Farrell GC.

J Lipid Res. 2015 Feb;56(2):277-85. doi: 10.1194/jlr.M053785. Epub 2014 Dec 17.

23.

Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of Diannexin (ASP8597).

Teoh NC, Ajamieh H, Wong HJ, Croft K, Mori T, Allison AC, Farrell GC.

PLoS One. 2014 Sep 15;9(9):e104376. doi: 10.1371/journal.pone.0104376. eCollection 2014.

24.

Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent.

Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC, Farrell GC.

J Hepatol. 2014 Dec;61(6):1376-84. doi: 10.1016/j.jhep.2014.07.024. Epub 2014 Jul 24.

PMID:
25064435
25.

Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.

Legry V, Van Rooyen DM, Lambert B, Sempoux C, Poekes L, Español-Suñer R, Molendi-Coste O, Horsmans Y, Farrell GC, Leclercq IA.

Clin Sci (Lond). 2014 Oct;127(7):507-18. doi: 10.1042/CS20140026.

PMID:
24766485
26.

Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection?

Chen S, Teoh NC, Chitturi S, Farrell GC.

J Gastroenterol Hepatol. 2014 Mar;29(3):435-41. doi: 10.1111/jgh.12422. Review.

PMID:
24199670
27.

Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.

Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J, Nguyen T, Heydet D, Delghingaro-Augusto V, Nolan CJ, Shackel NA, McLennan SV, Teoh NC, Larter CZ.

Liver Int. 2014 Aug;34(7):1084-93. doi: 10.1111/liv.12335. Epub 2013 Oct 25.

PMID:
24107103
28.

Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.

Larter CZ, Yeh MM, Haigh WG, Van Rooyen DM, Brooling J, Heydet D, Nolan CJ, Teoh NC, Farrell GC.

Obesity (Silver Spring). 2013 Jun;21(6):1189-99. doi: 10.1002/oby.20123. Epub 2013 May 10.

29.

Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis.

Pok S, Wen V, Shackel N, Alsop A, Pyakurel P, Fahrer A, Farrell GC, Teoh NC.

J Gastroenterol Hepatol. 2013 Sep;28(9):1545-54. doi: 10.1111/jgh.12216.

PMID:
23574010
30.

Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.

Van Rooyen DM, Gan LT, Yeh MM, Haigh WG, Larter CZ, Ioannou G, Teoh NC, Farrell GC.

J Hepatol. 2013 Jul;59(1):144-52. doi: 10.1016/j.jhep.2013.02.024. Epub 2013 Mar 7.

PMID:
23500152
31.

NAFLD in Asia--as common and important as in the West.

Farrell GC, Wong VW, Chitturi S.

Nat Rev Gastroenterol Hepatol. 2013 May;10(5):307-18. doi: 10.1038/nrgastro.2013.34. Epub 2013 Mar 5. Review.

PMID:
23458891
32.

JGH and me: a long and winding road-reflections of an outgoing Editor-in-Chief.

Farrell GC.

J Gastroenterol Hepatol. 2012 Dec;27(12):1768-71. doi: 10.1111/jgh.12001. No abstract available.

PMID:
23167523
33.

The JGH foundation: facilitating education and research in the Asia-Pacific.

Yeomans ND, Farrell GC.

J Gastroenterol Hepatol. 2012 Oct;27(10):1545. doi: 10.1111/j.1440-1746.2012.07237.x. No abstract available.

PMID:
22994432
34.

Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.

Wu CW, Farrell GC, Yu J.

J Gastroenterol Hepatol. 2012 Nov;27(11):1665-9. doi: 10.1111/j.1440-1746.2012.07213.x.

PMID:
22742931
35.

Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?

Chitturi S, Farrell GC.

J Gastroenterol Hepatol. 2012 Jun;27(6):993-4. doi: 10.1111/j.1440-1746.2012.07142.x. No abstract available.

PMID:
22621454
36.

A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice.

Heydet D, Chen LX, Larter CZ, Inglis C, Silverman MA, Farrell GC, Leroux MR.

Dev Neurobiol. 2013 Jan;73(1):1-13. doi: 10.1002/dneu.22031. Epub 2012 Jul 20.

37.

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

Farrell GC, van Rooyen D, Gan L, Chitturi S.

Gut Liver. 2012 Apr;6(2):149-71. doi: 10.5009/gnl.2012.6.2.149. Epub 2012 Apr 17.

38.

Liver cholesterol: is it playing possum in NASH?

Farrell GC, van Rooyen D.

Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G9-11. doi: 10.1152/ajpgi.00008.2012. Epub 2012 May 3. No abstract available.

39.

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.

Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN.

Hepatology. 2013 Jan;57(1):81-92. doi: 10.1002/hep.25789.

40.

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.

Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J.

Br J Cancer. 2012 Apr 24;106(9):1486-94. doi: 10.1038/bjc.2012.130.

41.

A thank you note from the editor-in-chief.

Farrell GC.

J Gastroenterol Hepatol. 2012 Jan;27(1):10. doi: 10.1111/j.1440-1746.2011.06993.x. No abstract available.

PMID:
22188026
42.

Histological features of non-alcoholic fatty liver disease: what is important?

Hashimoto E, Tokushige K, Farrell GC.

J Gastroenterol Hepatol. 2012 Jan;27(1):5-7. doi: 10.1111/j.1440-1746.2011.06957.x. No abstract available.

PMID:
22188024
43.

Hepatic endoplasmic reticulum stress in obesity: deeper insights into processes, but are they relevant to nonalcoholic steatohepatitis?

Leclercq IA, Van Rooyen DM, Farrell GC.

Hepatology. 2011 Dec;54(6):2260-5. doi: 10.1002/hep.24661. No abstract available.

PMID:
22139704
44.

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.

J Gastroenterol Hepatol. 2012 Feb;27(2):341-50. doi: 10.1111/j.1440-1746.2011.06939.x.

PMID:
21929649
45.

Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly.

Gan L, Chitturi S, Farrell GC.

Curr Gerontol Geriatr Res. 2011;2011:831536. doi: 10.1155/2011/831536. Epub 2011 Sep 12.

46.

Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?

Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J.

Hepatology. 2011 Dec;54(6):1998-2004. doi: 10.1002/hep.24581.

PMID:
21800340
47.

Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis.

Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC.

Gastroenterology. 2011 Oct;141(4):1393-403, 1403.e1-5. doi: 10.1053/j.gastro.2011.06.040. Epub 2011 Jun 23.

48.

SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH.

Van Rooyen DM, Farrell GC.

J Gastroenterol Hepatol. 2011 May;26(5):789-92. doi: 10.1111/j.1440-1746.2011.06704.x. No abstract available.

PMID:
21488942
49.

Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.

Bell-Anderson KS, Aouad L, Williams H, Sanz FR, Phuyal J, Larter CZ, Farrell GC, Caterson ID.

Int J Obes (Lond). 2011 Dec;35(12):1539-48. doi: 10.1038/ijo.2011.55. Epub 2011 Mar 8.

PMID:
21386801
50.

Identifying who is at risk of drug-induced liver injury: is human leukocyte antigen specificity the key?

Chitturi S, Farrell GC.

Hepatology. 2011 Jan;53(1):358-62. doi: 10.1002/hep.24094. No abstract available.

PMID:
21254184

Supplemental Content

Loading ...
Support Center